The rapid antidepressant effect of ketamine has become a breakthrough in the research and treatment of depression. Although predictive and modulating factors of the response to ketamine are broadly studied, little is known about optimal concurrent medication protocols. Concerning gamma-aminobutyric acid neurotransmission being a shared target for both ketamine and benzodiazepines (BZD), we evaluated the influence of BZD on the antidepressant effect of a single ketamine infusion in depressed patients. Data from 47 patients (27 females) with major depression (MADRS ≥ 20, ≥ 1 prior nonresponse to antidepressant treatment in current episode) who participated in two previous studies (EudraCT Number: 2009-010625-39 and 2013-000952-17) entered the analysis. All of the subjects were given an infusion of a subanesthetic dose of racemic ketamine (0.54 mg per kg) as an add-on medication to ongoing antidepressant treatment. Thirteen patients (28%) reached ≥ 50% reduction in MADRS within one week after ketamine administration. Nineteen (40%) patients took concomitant benzodiazepines on a daily basis. The doses of BZDs were significantly higher in nonresponders (p=0.007). ROC analysis distinguished responders from nonresponders by a criterion of >8mg of diazepam equivalent dose (DZ equivalent) with a sensitivity of 80% and a specificity of 85% (p<0.001). RM-ANOVA revealed a different time pattern of response to ketamine between the BZD+ (>8mg of DZ equivalent) and BZD- (≤8mg of DZ equivalent) groups, with a significantly worse outcome in BZD+ on day 3 (p=0.04) and day 7 (p=0.02). The results of the study indicate that concomitant benzodiazepine treatment in higher doses may attenuate ketamine's antidepressant effect. The pathophysiological, clinical and methodological implications of this finding should be considered in future research and ketamine treatment.

3rd Faculty of Medicine Charles University Prague Czechia

Clinical Research of Mental Disorders National Institute of Mental Health Klecany Czechia

See more in PubMed

Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Charney DS, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry (2000) 47:351–4. 10.1016/S0006-3223(99)00230-9 PubMed DOI

Xu Y, Hackett M, Carter G, Loo C, Gálvez V, Glozier N, et al. Effects of low-dose and very low-dose ketamine among patients with major depression: a systematic review and meta-analysis. IJNP (2016) 19(4):1–15. 10.1093/ijnp/pyv124 PubMed DOI PMC

Abdallah CG, Sanacora G, Duman RS, Krystal JH. Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics. Annu Rev Med (2015) 66:509–23. 10.1146/annurev-med-053013-062946 PubMed DOI PMC

Starsburger SE, Bhimani PM, Kaabe JH, Krysiak JT, Nanchanatt DL, Nguyen TN, et al. What is the mechanism of ketamine’s rapid-onset antidepressant effect? A concise overview of the surprisingly large of possibilities. J Clin Pharm Ther (2017) 42(2):147–54. 10.1111/jcpt.12497 PubMed DOI

Zarate CA, Manji HK. The role of AMPA receptor modulation in the treatment of neuropsychiatric diseases. Exp Neurol (2008) 211(1):7–10. 10.1016/j.expneurol.2008.01.011 PubMed DOI PMC

Koike H, Iijima M, Chaki S. Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression. Behav Brain Res (2011) 224(1):107–11. 10.1016/j.bbr.2011.05.035 PubMed DOI

Garcia LS, Comim CM, Valvassori SS, Reus GZ, Barbosa LM, Andreazza AC, et al. Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neuropsychopharmacol Biol Psychiatry (2008) 32(1):140–4. 10.1016/j.pnpbp.2007.07.027 PubMed DOI

Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, et al. mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science (2010) 329:959–64. 10.1126/science.1190287 PubMed DOI PMC

Blier P. Exploiting N-Methyl-D-aspartate channel blockade for a rapid antidepressant response in major depressive disorder. Biol Psychiatry (2013) 74(4):238–9. 10.1016/j.biopsych.2013.05.029 PubMed DOI

Wilkinson ST, Sanacora G. Consideration on the off-label use of ketamine as a treatment for mood disorders. JAMA (2017) 318(9):793–4. 10.1001/jama.2017.10697 PubMed DOI PMC

Sanacora G, Katz R. Ketamine: a review for clinicians. Focus (Am Psychiatr Publ) (2018) 16(3):243–50.  10.1176/appi.focus.20180012 PubMed DOI PMC

Fassaert T, Dorn T, Spreeuwenberg PM, van Dongen MC, van Gool CJ, Yzermans CJ. Prescription of benzodiazepines in general practice in the context of a man-made disaster: a longitudinal study. Eur J Public Health (2007) 17:612–7. 10.1093/eurpub/ckm020 PubMed DOI

Olfson M, King M, Schoenbaum M. Benzodiazepine use in the United States. JAMA Psychiatry (2015) 72(2):136–42.  10.1001/jamapsychiatry.2014.1763 PubMed DOI

American Psychiatric Association Treatment of patients with major depression and practical guideline. American Psychiatric Association; (2010). [cited 2018 Jan 28]. Available at: http://www.psychiatryonline.com/pracGuide/pracGuideTopic_7.aspx

Kennedy SH, Lam RW, Mclntyre RS, Tourjman SV, Bhat V, Blier P, et al. Canadian network for mood and anxiety treatments (CANMAT) 2016 clinical guidelines for the management of adults with major depressive disorder. Section 3: pharmacological treatments. Can J Psychiatry (2016) 61(9):540–60. 10.1177/0706743716659417 PubMed DOI PMC

Bushnell GA, Sturmer T, Gaynes BN, Pate V, Miller M. Simultaneous antidepressant and benzodiazepine new use and subsequent long-term benzodiazepine use in adults with depression, United States, 2001-2014. JAMA Psychiatry (2017) 74(7):747–55.  10.1001/jamapsychiatry.2017.1273 PubMed DOI PMC

Sjostedt C, Ohlsson H, Xinjun L, Sundquist K. Socio-demographic factors and long-term use of benzodiazepines in patients with depression, anxiety or insomnia. Psych Res (2017) 249:221–5. 10.1016/j.psychres.2017.01.046 PubMed DOI

Valenstein M, Taylor KK, Austin K, Kales HC, McCarthy JF, Blow FC. : Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry (2004) 161:654–61.  10.1176/appi.ajp.161.4.654 PubMed DOI

Sanyal C, Asbridge M, Kisely S, Sketris I, Andreou P. The utilization of antidepressants and benzodiazepines among people with major depression in Canada. Can J Psychiatry (2011) 56:667–76.  10.1177/070674371105601105 PubMed DOI

Parker GB, Graham RK. Determinants of treatment-resistant depression. The salience of benzodiazepines. J Nerv Ment Dis (2015) 203(9):659–63. 10.1097/NMD.0000000000000348 PubMed DOI

Costa E, Guidotti A, Mao CC. Evidence for involvement of GABA in the action of benzodiazepines: studies on rat cerebellum. Adv Biochem Psychopharmacol (1975) 14:113–30. PubMed

Downing SS, Lee YT, Farb DH, Gibbs TT. Benzodiazepine modulation of partial agonist efficacy and spontaneously active GABA(A) receptors supports an allosteric model of modulation. Br J Pharmacol (2005) 145:894–906. 10.1038/sj.bjp.0706251 PubMed DOI PMC

Eintrei C, Sokoloff L, Smith CB. Effects of diazepam and ketamine administered individually or in combination on regional rates of glucose utilization on rat brain. Br J Anaest (1999) 82:596–602. 10.1093/bja/82.4.596 PubMed DOI

Irifune M, Sato T, Kamata Y, Nishikawa T, Nomoto M, Fukuda T, et al. Inhibition by diazepam of ketamine-induced hyperlocomotion and dopamine turnover in mice. Can J Anaesth (1998) 45(5):471–8. 10.1007/BF03012584 PubMed DOI

Catwright PD, Pingel SM. Midazolam and diazepam in ketamine anaesthesia. Anaesthesia (1984) 39(5):439–42. 10.1111/j.1365-2044.1984.tb07312.x PubMed DOI

Freuchen I, Ostergaard J, Kuhl JB, Mikkelsen BO. Reduction of psychotomimetic side effects of Ketalar (ketamine) by Rohypnol (flunitrazepam). A randomized, double-blind trial. Acta Anaesth Scand (1976) 20(2):97–103. 10.1111/j.1399-6576.1976.tb05015.x PubMed DOI

Ford N, Ludbrook G, Galletly Ch. Benzodiazepines may reduce the effectiveness of ketamine in the treatment of depression. Aust N Z J Psychiatry (2015) 49(12):1227. 10.1177/0004867415590631 PubMed DOI

Frye MA, Blier P, Tye SJ. Concomitant benzodiazepine use attenuates ketamine response: implications for large scale study design and clinical development. J Clin Psychofarmacol (2015) 35(3):334–6. 10.1097/JCP.0000000000000316 PubMed DOI

Albott CS, Shiroma PR, Cullen KR, Johns B, Thuras P, Wels J, et al. The antidepressant effect of repeat dose intravenous ketamin is delayed by concurrent benzodiazepine use. J Clin Psychiatry (2017) 78(3):e308–209. 10.4088/JCP.16l11277 PubMed DOI

Sos P, Klirova M, Novak T, Kohutova B, Horacek J, Palenicek T. Relationship of ketamine’s antidepressant and psychotomimetic effects in unipolar depression. Neuro Endocrinol Lett (2013) 34(4):287–93. PubMed

American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Publishing; (2009).

Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E, et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry (1998) 59:22–33. 10.1037/t18597-000 PubMed DOI

Montgomery SA, Asberg M. A new depression scale designed to be sensitive to change. Br J Psychiatr (1979) 134:382–9. 10.1192/bjp.134.4.382 PubMed DOI

Kane SP. Equivalent Benzodiazepine Canculator (2017). Available from: http://clincalc.com/Benzodiazepine/

Hetem LA, Danion JM, Diemunsch P, Brandt C. Effect of a subanesthetic dose of ketamine on memory and conscious awareness in healthy volunteers. Psychopharmacology (2000) 152:283–8. 10.1007/s002130000511 PubMed DOI

Horacek J, Brunovsky M, Novak T, Tislerova B, Palenicek T, Bubenikova-Valesova V, et al. Subanesthetic dose of ketamine decreases prefrontal theta cordance in healthy volunteers: implications for antidepressant effect. Psychol Med (2010) 40:1443–51. 10.1017/S0033291709991619 PubMed DOI

Penders J, Verstraete A. Laboratory guidelines and standards in clinical and forensic toxicology. Accred Qual Assur (2006) 11:284–90. 10.1007/s00769-006-0131-y DOI

Hayasaka Y, Purgato M, Magni LR, Ogawa Y, Takeshima N, Cipriani A, et al. Dose equivalents of antidepressants: Evidence-based recommendations from randomized controlled trials. J Affect Disord (2015) 180:179–84. 10.1016/j.jad.2015.03.021 PubMed DOI

Luckenbaugh DA, Niciu MJ, Ionescu DF, Nolan NM, Richards EM, Brutsche EM, et al. Do the dissociative side effects of ketamine mediate its antidepressant effects? J Affect Disord (2014) 159:56–61. 10.1016/j.jad.2014.02.017 PubMed DOI PMC

Du J, Machado-Vieira R, Maeng S, Martinowich K, Manji HK, Zarate CA., , Jr Enhancing AMPA to NMDA throughput as a convergent mechanism for antidepressant action. Drug Discovery Today Ther Strated (2006) 3(4):519–26. 10.1016/j.ddstr.2006.11.012 PubMed DOI PMC

Maeng S, Zarate CA, Jr, Du J, Schloesser RJ, McCammon J, Chen G, et al. Cellular mechanisms underlying the antidepressant effects of ketamine: role of alpha-amino-3-hydroxy-mathylisoxazole-4-propionic acid receptors. Biol Psychiatry (2008) 63(4):349–52. 10.1016/j.biopsych.2007.05.028 PubMed DOI

Cavalleri L, Merlo Pich E, Millan MJ, Chiamulera C, Kunath T, Spano PF, et al. Ketamine enhances structural plasticity in mouse mesencephalic and human iPSC-derived dopaminergic neurons via AMPAR-driven BDNF and mTOR signalling. Mol Psychiatry (2018) 23(4):812–23.  10.1038/mp.2017.241 PubMed DOI

Sanderson C, Hardy J, Odette S, Currow DC. Placebo and nocebo effects in randomized controlled trials: the implications for research and practice. J Pain Symptom Manage (2013) 46(5):722–30. 10.1016/j.jpainsymman.2012.12.005 PubMed DOI

Krystal JH, Karper LP, Seibyl JP, Freeman GK, Delaney R, Bremner D, et al. Subanestetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive and neuroendocrine responses. Arch Gen Psychiatry (1994) 51(3):199–214. 10.1001/archpsyc.1994.03950030035004 PubMed DOI

Fava M, Rush AJ, Alpert JE, Balasubramani GK, Wisniewski SR, Carmin CN, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry (2008) 165(3):342–51. 10.1176/appi.ajp.2007.06111868 PubMed DOI

Vigo DV, Baldessarini RJ. Anticonvulsants in the treatment of major depressive disorder: an overview. Har Rev Psychiatry (2009) 17(4):231–41. 10.1080/10673220903129814 PubMed DOI

Anand A, Charney DS, Oren DA, Berman RM, Hu XS, Cappiello A, et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine: support for hyperglutamatergic effects of N-methyl-D-aspartate receptor antagonists. Arch Gen Psychiatry (2000) 57(3):270–6. 10.1001/archpsyc.57.3.270 PubMed DOI

Deakin JF, Lees J, McKie S, Hallak JE, Williams SR, Dursun SM. Glutamate and the neural basis of the subjective effects of ketamine: a pharmaco-magnetic resonance imaging study. Arch Gen Psychiatry (2008) 65(2):154–64. 10.1001/archgenpsychiatry.2007.37 PubMed DOI

Doyle OM, De Simoni S, Schwarz AJ, Brittain C, O’Daly OG, Williams SC, et al. Quantifying the attenuation of the ketamine pharmacological magnetic resonance imaging response in humans: a validation using antipsychotic and glutamatergic agents. J Pharmacol Exp Ther (2013) 345(1):151–60. 10.1124/jpet.112.201665 PubMed DOI

Li CT, Yang KC, Lin WC. Glutamatergic dysfunction and glutamatergic compounds for major psychiatric disorders: evidence from clinical neuroimaging studies. Front Psychiatry (2018) 9:767.  10.3389/fpsyt.2018.00767 PubMed DOI PMC

Bajbouj M, Lisanby SH, Lang UE, Danker-Hopfe H, Heuser I, Neu P. Evidence for impaired cortical inhibition in patients with unipolar major depression. Biol Psychiatry (2006) 59(5):395–400. 10.1016/j.biopsych.2005.07.036 PubMed DOI

Jeng JS, Li CT, Lin HC, Tsai SJ, Bai YM, Su TP, et al. Antidepressant-resistant depression is characterised by reduced short-a nd long-interval cortical inhibition. Psychol Med (2019) 50(8):1–7. 10.1017/S0033291719001223 PubMed DOI

International pooled patient-level meta-analysis of ketamine infusion for depression: In search of clinical moderators